Abstract
Vitamin D is essential in bone mineralization and calcium homeostasis, and an increasing body of evidence suggests that vitamin D may be important for maintaining extraskeletal health, including having beneficial effects on cardiometabolic outcomes. Vitamin D deficiency is widespread, but the role of vitamin D in the metabolic syndrome is not fully elucidated. In this review we summarize data from observational studies and randomized controlled trials on the relation between vitamin D and the metabolic syndrome and its components. A large number of observational studies suggest a relationship between low levels of 25(OH)D and the metabolic syndrome or its individual clinical features. Randomized controlled trials of vitamin D supplementation addressing aspects of the metabolic syndrome have yielded inconsistent results, and many studies suffer from methodological limitations. There is an urgent need for large, well-designed randomized controlled trials with relevant endpoints. Until definitive results from such studies are available, caution should be taken towards the use of vitamin D-supplementation for disorders other than musculoskeletal system. New molecular biological techniques elucidating the interaction between the active vitamin D derivatives and target genes represent a promising approach to more precise knowledge about new biomedical function, which also might shed light on the complex metabolic syndrome.
Keywords: Cholecalciferol, glucose metabolism, hypertension, insulin resistance, lipids, metabolic syndrome, obesity, review, vitamin D, VDR, 25(OH)D
Current Vascular Pharmacology
Title:Vitamin D and the Metabolic Syndrome
Volume: 11 Issue: 6
Author(s): Hanne L. Gulseth, Ingrid M.F. Gjelstad, Kare I. Birkeland and Christian A. Drevon
Affiliation:
Keywords: Cholecalciferol, glucose metabolism, hypertension, insulin resistance, lipids, metabolic syndrome, obesity, review, vitamin D, VDR, 25(OH)D
Abstract: Vitamin D is essential in bone mineralization and calcium homeostasis, and an increasing body of evidence suggests that vitamin D may be important for maintaining extraskeletal health, including having beneficial effects on cardiometabolic outcomes. Vitamin D deficiency is widespread, but the role of vitamin D in the metabolic syndrome is not fully elucidated. In this review we summarize data from observational studies and randomized controlled trials on the relation between vitamin D and the metabolic syndrome and its components. A large number of observational studies suggest a relationship between low levels of 25(OH)D and the metabolic syndrome or its individual clinical features. Randomized controlled trials of vitamin D supplementation addressing aspects of the metabolic syndrome have yielded inconsistent results, and many studies suffer from methodological limitations. There is an urgent need for large, well-designed randomized controlled trials with relevant endpoints. Until definitive results from such studies are available, caution should be taken towards the use of vitamin D-supplementation for disorders other than musculoskeletal system. New molecular biological techniques elucidating the interaction between the active vitamin D derivatives and target genes represent a promising approach to more precise knowledge about new biomedical function, which also might shed light on the complex metabolic syndrome.
Export Options
About this article
Cite this article as:
Gulseth L. Hanne, Gjelstad M.F. Ingrid, Birkeland I. Kare and Drevon A. Christian, Vitamin D and the Metabolic Syndrome, Current Vascular Pharmacology 2013; 11 (6) . https://dx.doi.org/10.2174/15701611113119990169
DOI https://dx.doi.org/10.2174/15701611113119990169 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease
Current Alzheimer Research Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Non-Alcoholic Steatohepatitis: New Insights from OMICS Studies
Current Pharmaceutical Biotechnology Synthesis and Biological Potentials of Quinoline Analogues: A Review of Literature
Mini-Reviews in Organic Chemistry Recent Patents on the Upgrading of Fish by-Products
Recent Patents on Chemical Engineering Amelioration of Cisplatin Induced Nephrotoxicity by Standardized Methanolic Extract of Roots of Boerhaavia diffusa
The Natural Products Journal MCM-41-SO3H as an Advanced Nanocatalyst for the Solvent-Free Synthesis of N-aryl-2-amino-1,6-naphthyridine Derivatives
Current Nanoscience Blood Pressure and Cognitive Impairment in the Elderly
Current Hypertension Reviews Depression, Antidepressants and Hypertensive Disorders of Pregnancy: A Systematic Review
Current Drug Safety Circulating and Vascular Bioactive Factors During Hypertension in Pregnancy
Current Bioactive Compounds Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs
Current Pharmaceutical Design Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage
Current Molecular Medicine Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Cardiovascular Disease and Dyslipidemia: Beyond LDL
Current Pharmaceutical Design Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents
Current Neurovascular Research Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease
Current Vascular Pharmacology Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry Non-Communicable Diseases and Adherence to Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets